Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

Abstract Background The cholinergic system and M1 receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M1 receptor partial agonist HTL0018318 is under development for the symptomatic treatment of Dementia’s including Alzheimer’s disease (AD) and demen...

Full description

Bibliographic Details
Main Authors: Charlotte Bakker, Tim Tasker, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Robert Jan Doll, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm Weir, Fiona H. Marshall, David M. Cross, Geert Jan Groeneveld, Pradeep J. Nathan
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Alzheimer’s Research & Therapy
Subjects:
Muscarinic M1
M1 receptor
Cholinergic
Dementia
Safety
Pharmacokinetics
Online Access:https://doi.org/10.1186/s13195-021-00816-5

Internet

https://doi.org/10.1186/s13195-021-00816-5

Similar Items